Zeke Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-2,584
Closed -$341K 313
2021
Q2
$341K Buy
2,584
+342
+15% +$44.8K 0.02% 191
2021
Q1
$288K Sell
2,242
-423
-16% -$52.1K 0.02% 219
2020
Q4
$318K Buy
2,665
+259
+11% +$31.6K 0.03% 187
2020
Q3
$275K Hold
2,406
0.03% 170
2020
Q2
$274K Buy
+2,406
New +$255K 0.05% 151
2020
Q1
Sell
-18,628
Closed -$1.99M 309
2019
Q4
$1.99M Buy
18,628
+5,870
+46% +$612K 0.17% 109
2019
Q3
$1.36M Sell
12,758
-355
-3% -$36.4K 0.12% 141
2019
Q2
$1.33M Sell
13,113
-5
-0% -$480 0.13% 141
2019
Q1
$1.18M Sell
13,118
-7,328
-36% -$635K 0.11% 159
2018
Q4
$1.7M Buy
20,446
+517
+3% +$48.5K 0.16% 105
2018
Q3
$2.15M Buy
19,929
+15,205
+322% +$1.67M 0.18% 89
2018
Q2
$519K Hold
4,724
0.05% 296
2018
Q1
$474K Hold
4,724
0.04% 339
2017
Q4
$465K Buy
+4,724
New +$448K 0.05% 303

Other funds holding DGX

Zeke Capital Advisors's DGX Position: Q3 2021 in Review

Zeke Capital Advisors sold out of Quest Diagnostics (DGX) in Q3 2021, closing a stake of 2,584 shares — an estimated $341K sold.

Zeke Capital Advisors first reported a position in DGX in Q4 2017 and held it in 14 quarters. The position peaked at $2.15M in Q3 2018. 837 funds tracked by Wall St. Rank hold DGX as of Q3 2021.

  • Zeke Capital Advisors reported no remaining Quest Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Zeke Capital Advisors sold 2,584 Quest Diagnostics shares in Q3 2021, an estimated $341K.
  • Zeke Capital Advisors first reported a position in Quest Diagnostics in Q4 2017 and held it in 14 quarters.
  • Zeke Capital Advisors's Quest Diagnostics position peaked at $2.15M in Q3 2018.
  • 837 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2021.

Based on Zeke Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.